LY4057996 SC + LY4057996 IV + Placebo SC + Placebo IV + Degludec SC + Lispro SC + Degludec IV + Pre-study basal insulin SC

Phase 1Recruiting
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetes Mellitus, Type 1

Conditions

Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2

Trial Timeline

May 16, 2025 โ†’ Dec 1, 2026

About LY4057996 SC + LY4057996 IV + Placebo SC + Placebo IV + Degludec SC + Lispro SC + Degludec IV + Pre-study basal insulin SC

LY4057996 SC + LY4057996 IV + Placebo SC + Placebo IV + Degludec SC + Lispro SC + Degludec IV + Pre-study basal insulin SC is a phase 1 stage product being developed by Eli Lilly for Diabetes Mellitus, Type 1. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06945406. Target conditions include Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06945406Phase 1Recruiting